TY - JOUR
T1 - Update on G-protein polymorphisms in hypertension
AU - Zhu, Haidong
AU - Wang, Xiaoling
AU - Lu, Yanhui
AU - Poola, Joseph
AU - Momin, Zamena
AU - Harshfield, Gregory A
AU - Snieder, Harold
AU - Dong, Yanbin
PY - 2006/4
Y1 - 2006/4
N2 - The classic candidate gene approach continues to be the most prevalent tool in the search for the genetic basis of essential hypertension. With the list of candidate genes for this disorder steadily increasing, the pertussis toxin-sensitive inhibitory G protein (G1) protein β3 subunit (GNB3) gene has remained "sizzling," challenging the domination of the renin-angiotensin system. Is the genetic variability of GNB3 a causative factor underlying the pathogenesis of essential hypertension? Is the "functional" polymorphism, C825T, only "another" of the countless single nucleotide polymorphisms (SNP) for this disorder after all? As such, does its presence merely reinforce our confidence that essential hypertension is indeed polygenic? Should the C825T polymorphism be used in clinical practice and individualized antihypertensive treatment? Currently, there are still more questions than answers. In this review, in conjunction with our own research, we bring readers up to date on the latest developments of GNB3 polymorphisms in the field of hypertension.
AB - The classic candidate gene approach continues to be the most prevalent tool in the search for the genetic basis of essential hypertension. With the list of candidate genes for this disorder steadily increasing, the pertussis toxin-sensitive inhibitory G protein (G1) protein β3 subunit (GNB3) gene has remained "sizzling," challenging the domination of the renin-angiotensin system. Is the genetic variability of GNB3 a causative factor underlying the pathogenesis of essential hypertension? Is the "functional" polymorphism, C825T, only "another" of the countless single nucleotide polymorphisms (SNP) for this disorder after all? As such, does its presence merely reinforce our confidence that essential hypertension is indeed polygenic? Should the C825T polymorphism be used in clinical practice and individualized antihypertensive treatment? Currently, there are still more questions than answers. In this review, in conjunction with our own research, we bring readers up to date on the latest developments of GNB3 polymorphisms in the field of hypertension.
UR - http://www.scopus.com/inward/record.url?scp=33646047704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646047704&partnerID=8YFLogxK
U2 - 10.1007/s11906-006-0037-4
DO - 10.1007/s11906-006-0037-4
M3 - Review article
C2 - 16600156
AN - SCOPUS:33646047704
SN - 1522-6417
VL - 8
SP - 23
EP - 29
JO - Current Hypertension Reports
JF - Current Hypertension Reports
IS - 1
ER -